GPRC5B (G Protein-Coupled Receptor Class C Group 5 Member B) is an orphan receptor within the GPCR superfamily, characterized by a seven-transmembrane domain structure and extracellular ligand-binding regions. Though its endogenous ligand remains unidentified, GPRC5B is implicated in lipid metabolism, adipose tissue regulation, and cellular differentiation. Studies link it to metabolic disorders, neurodegenerative diseases, and cancers, particularly through interactions with signaling pathways like Wnt/β-catenin and EGFR.
GPRC5B antibodies are critical tools for detecting and quantifying the receptor in techniques such as Western blotting, immunohistochemistry, and flow cytometry. These antibodies typically target extracellular or intracellular epitopes, enabling research into its tissue-specific expression, subcellular localization, and disease-related dysregulation. Commercial antibodies are often validated for cross-reactivity and specificity across species, though challenges persist due to structural similarities with other GPCR family members.
Current research leverages GPRC5B antibodies to explore its role in obesity, insulin resistance, and tumor progression. Recent findings suggest it may modulate lipid storage in adipocytes and influence cancer cell proliferation. However, functional ambiguity persists, driving demand for high-quality antibodies to dissect its mechanistic pathways and therapeutic potential.